GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone

 
• By Jessica Merrill

GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.

Fist Bump
GSK has teamed up with iTeos on a TIGIT antibody • Source: Alamy

More from Anticancer

More from Therapy Areas